Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Never miss an options trading signal again: unusual options activity screeners and strategies. FREE 30 Day Trial

Stocks | Futures | Watchlist | More
or

Adamis Pharmaceuticl (ADMP)

Adamis Pharmaceuticl (ADMP)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 27,882
  • Shares Outstanding, K 149,983
  • Annual Sales, $ 2,210 K
  • Annual Income, $ -45,830 K
  • 60-Month Beta 1.05
  • Price/Sales 12.95
  • Price/Cash Flow N/A
  • Price/Book 10.05
Trade ADMP with:
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -0.16
  • Most Recent Earnings -0.03 on 11/14/22
  • Next Earnings Date N/A
  • Annual Dividend & Yield 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Options Overview Details

View History
  • Implied Volatility 361.15% ( +361.15%)
  • Historical Volatility 94.27%
  • IV Percentile 90%
  • IV Rank 33.49%
  • IV High 1,017.94% on 11/22/22
  • IV Low 30.40% on 04/01/22
  • Put/Call Vol Ratio 0.00
  • Today's Volume 2
  • Volume Avg (30-Day) 44
  • Put/Call OI Ratio 0.00
  • Today's Open Interest 1
  • Open Int (30-Day) 21,856

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.1272 +46.15%
on 11/02/22
0.2330 -20.21%
on 11/15/22
+0.0496 (+36.39%)
since 10/25/22
3-Month
0.1200 +54.92%
on 10/11/22
0.3740 -50.29%
on 09/20/22
-0.1533 (-45.19%)
since 08/25/22
52-Week
0.1200 +54.92%
on 10/11/22
0.8477 -78.07%
on 01/10/22
-0.6325 (-77.28%)
since 11/24/21

Most Recent Stories

More News
Adamis: Q3 Earnings Snapshot

Adamis: Q3 Earnings Snapshot

ADMP : 0.1859 (-2.52%)
Adamis Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Corporate Update

Management to host webcast/conference call today at 1:30 p.m. PT / 4:30 p.m. ...

ADMP : 0.1859 (-2.52%)
Adamis Pharmaceuticals Schedules Second Quarter 2022 Financial Results Conference Call and Corporate Update

SAN DIEGO, Aug. 08, 2022 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP), a biopharmaceutical company developing and...

ADMP : 0.1859 (-2.52%)
Leading Independent Proxy Advisory Firm ISS Recommends Adamis Pharmaceuticals’ Stockholders Vote FOR Critical Proposals at Upcoming Annual Meeting

ISS Recommends Stockholders Support Key Proposals Pertaining to a Reverse Stock Split and New Equity Incentive Plan The Deadline for Stockholders to Vote...

ADMP : 0.1859 (-2.52%)
Adamis Pharmaceuticals Provides Update on Clinical Study Assessing Tempol for the Treatment of COVID-19

Interim DSMB review expected in late September...

ADMP : 0.1859 (-2.52%)
Adamis Pharmaceuticals Issues Letter to Stockholders

SAN DIEGO, July 21, 2022 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP), a biopharmaceutical company developing and...

ADMP : 0.1859 (-2.52%)
Blackberry Considers Alternative To Selling Catapults As Continuation Of Covid-19 Means More Room For Adamis Pharmaceuticals Corp.

As an alternative to the $600 million non-core intellectual asset transaction it had agreed to with Catapult IP Innovations, BlackBerry

BB : 4.84 (+0.62%)
ADMP : 0.1859 (-2.52%)
What Makes Adamis (ADMP) a New Buy Stock

Adamis (ADMP) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

ADMP : 0.1859 (-2.52%)
Adamis Appoints Vickie Reed to Board of Directors

New Director Named with Significant Executive Management and Financial Leadership Experience...

ADMP : 0.1859 (-2.52%)
Adamis Pharmaceuticals Announces Leadership Transition to Support New Phase of Innovation and Growth

David J. Marguglio, Co-Founder and Chief Business Officer, Appointed President and CEO Dennis J. Carlo, Ph.D., Has Retired as Both CEO and Board Director ...

ADMP : 0.1859 (-2.52%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 56% Sell with a Average short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Adamis Pharmaceuticals Corporation, formerly Cellegy Pharmaceuticals, Inc., is a specialty pharmaceutical company engaged engages in the research, development, and commercialization of prescription medicines for the treatment of viral infections. Adamis Pharmaceuticals is composed of two wholly owned...

See More

Key Turning Points

3rd Resistance Point 0.1936
2nd Resistance Point 0.1917
1st Resistance Point 0.1888
Last Price 0.1859
1st Support Level 0.1840
2nd Support Level 0.1821
3rd Support Level 0.1792

See More

52-Week High 0.8477
Fibonacci 61.8% 0.5697
Fibonacci 50% 0.4839
Fibonacci 38.2% 0.3980
Last Price 0.1859
52-Week Low 0.1200

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar